The F‐prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma. (29th January 2013)

• Record Type: Journal Article
• Authors: Akiyama, Kosuke; Ohga, Noritaka; Maishi, Nako; Hida, Yasuhiro; Kitayama, Kazuko; Kawamoto, Taisuke; Osawa, Takahiro; Suzuki, Yuko; Shinohara, Nobuo; Nonomura, Katsuya; Shindoh, Masanobu; Hida, Kyoko
• Is Part Of: Pathology international. Volume 63:Number 1(2013:Jan.)
• Page Start: 37
• Page End: 44
• Publication Date: 2013-01-29
• Subjects: Pathology -- Periodicals; 616.07
• DOI: 10.1111/pin.12031
• Languages: English
• ISSNs: 1320-5463

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Tumor angiogenesis is necessary for tumor progression and metastasis; therefore, tumor blood vessels are potential therapeutic targets in anticancer therapy. We previously reported that tumor endothelial cells (TECs) exhibit different phenotypes compared with normal endothelial cells (NECs), and microarray analyses of mouse TECs and NECs have shown that several genes are upregulated in TECs compared with NECs. Among these genes, the expression levels of prostaglandin F receptor (PTGFR) mRNA, which encodes the prostaglandin F receptor (FP), were higher in TECs than in NECs. It has been reported that FP and its ligand, prostaglandin <italic>F</italic>_2α, are involved in tumor angiogenesis. However, there have been no reports of the expression of PTGFR in the tumor vessels of renal cell carcinoma (RCC). Thus, we isolated human TECs (hTECs) from RCCs. The expression levels of PTGFR mRNA were also upregulated in hTECs. In addition, immunostaining showed that the PTGFR was expressed in human tumor blood vessels <italic>in vivo</italic>. These findings suggested that PTGFR is a novel TEC marker and that it may be a novel target for antiangiogenic therapy for RCC.</p> </abstract>